Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Fuchs Endothelial Corneal Dystrophy
NCT04440280Phase 2Recruiting
- Sponsor
- Massachusetts Eye and Ear
- Start
- Sep 2020
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acetylcysteine in Fuchs endothelial corneal dystrophy (FECD), sponsored by Massachusetts Eye and Ear. Started Sep 2020; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
Fuchs endothelial corneal dystrophy (FECD)
Beyond the preview
Go deeper on NCT04440280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440280.